循环miR-145和miR-484在乳腺癌诊断中的研究

Research of circulating miR-145 and miR-484 in the diagnosis of breast cancer

目的探索乳腺癌血浆中差异表达的微小RNA（miRNA）,为检测乳腺癌寻找全新的生物标志物,并确定其诊断价值。方法采用定量反转录聚合酶反应检测训练组30例乳腺癌患者和20例健康对照者血浆中的候选标志物,再盲法验证20例乳腺癌患者和20例健康对照者候选标志物的诊断效能。结果训练组共发现6个差异表达的miRNA,其中miR-145和miR-484差异最显著,与其他4个差异有统计学意义（P〈0.05）。经盲法验证,二者联合诊断可有效区分乳腺癌患者与健康对照患者,受试者工作曲线下面积为0.965,灵敏度和特异度分别为91.3%（95%CI：85.2%-95.4%）和90.8%（95%CI：83.7%-93.6%）,阳性预测值为91.0%,阴性预测值为91.0%。结论血浆中miR-145和miR-484是乳腺癌潜在的诊断标志物。

Objective To explore the expression changes of miRNAs in the plasma of patients with breast cancer and to evaluate their significance,so as to find new biomarkers for the detection of breast cancer.Methods Plasma miRNA levels of 30 cases of patients with breast cancer and 20 cases of healthy controls in training group were measured by qRT-PCR.The diagnosis values of the candidate miRNAs were validated by blind method in test group（including 20 cases of patients with breast cancer and 20 cases of healthy controls）.Results In training group,there were 6differentially expressed miRNAs（P0.05）,in which miR-145 and miR-451 expressed significantly different from the other 4miRNAs（P0.05）.The result of blind validation showed that a combination of miR-145 and miR-484 could be effective in the differential diagnosis between patients with breast cancer and healthy controls.And the AUC,sensitivity,specificity,positive predictive value and negative predictive value of combination detection were 0.965,91.3%（95%CI 85.2%-95.4%）,90.8%（95%CI83.7%-93.6%）,91.0% and 91.0%,respectively.Conclusion Plasma miR-145 and miR-484 could be potential specific biomarkers for breast cancer screening.